Hailshadow/iStock via Getty Images
- Shares of Annovis Bio (NYSE:ANVS) more than doubled in value on Tuesday after the company said its lead asset, buntanetap, was found to be safe and effective in improving the physical and cognitive functions of patients with early Parkinson’s disease.
- Updating data from its Phase 3 PD trial, Annovis (ANVS) said buntanetap, designed to target neurotoxic proteins, maintained cognition in the entire patient population at 10 and 20 mg doses, while those on placebo deteriorated throughout the study.
- At 20 mg, the study drug “showed significant improvement in cognition compared to placebo,” the company added.
- With a consistent tolerability profile across early and advanced PD patients, buntanetap led to statistically significant improvements in all primary and secondary endpoints in specific subgroups, according to Annovis Bio (ANVS).
- The company has scheduled a webcast at 4:30 PM ET on July 2 to discuss additional results.